查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1649508

中樞早熟症(Cpp) 治療市場：預測（2025-2030 年）

Central Precocious Puberty (Cpp) Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

中樞早熟症(Cpp) 治療市場預計將從 2025 年的 16,348.72 億美元成長到 2030 年的 23,848.72 億美元，複合年成長率為 7.84%。

中樞早熟症(Cpp) 治療涉及藥物治療，旨在管理和延緩因下丘腦-垂體-性腺 (HPG) 軸過早激活而導致的早熟症。性早熟的定義是女孩在8歲前、男孩在9歲前出現第二性徵。主要治療方法是使用促性腺激素分泌釋放激素 (GnRH)促效劑，阻止性激素的分泌並減緩或阻止青春期的進程。藥物治療會延遲成熟，在某些情況下可以考慮手術。血液檢查、MRI、 電腦斷層掃描和X光等診斷工具可以幫助確定是否需要治療。男性和女性均可接受治療方法，主要在醫院、專科診所、居家照護機構和其他醫療機構進行。

中樞早熟症(Cpp) 治療市場促進因素

  • 荷爾蒙失調盛行率不斷上升：荷爾蒙失調盛行率不斷上升預計將在未來幾年顯著推動 CPP 治療市場的成長。荷爾蒙失調包括體內荷爾蒙失衡而引起的多種病症。現代生活方式、環境暴露以及遺傳或表觀遺傳因素導致這些疾病的盛行率不斷上升。治療 CPP 的主要目標是透過抑制觸發青春期的訊號來控制荷爾蒙失衡引起的早熟症。因此，荷爾蒙異常發生率的增加是推動CPP治療市場發展的關鍵因素。

地理視角

  • 亞太地區快速成長：亞太地區對 CPP 治療的需求大幅成長，並且隨著人們認知的提高、醫療保健系統的改善和疾病盛行率的上升，預計還將繼續成長。診斷能力的提高、家長和醫療保健專業人員意識的增強以及潛在的環境影響都促成了這一趨勢。都市化和生活方式的改變改變了人們的飲食習慣，增加了人們接觸內分泌干擾物質的機會，這可能導致早熟症。宣傳宣傳活動和教育計劃在鼓勵兒童早期診斷和治療 CPP 方面也發揮著重要作用。

為什麼要購買這份報告？

  • 深刻分析：獲得深入的市場洞察，涵蓋主要和新興地區，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問公司、中小企業和大型企業都有益且具有成本效益。

它有什麼用途？

產業與市場分析、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2030 年的實際資料和預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭定位、策略與市場佔有率分析
  • 各細分市場及各地區（包括國家）的收益成長及預測分析
  • 公司概況（策略、產品、財務、主要發展等）

目錄

第 1 章 簡介

  • 市場概況
  • 市場定義
  • 研究範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 研究過程

第3章執行摘要

  • 主要發現
  • CXO觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

5. 中樞早熟症(Cpp) 治療市場（依藥物類型）

  • 介紹
  • 亮丙瑞林
  • 希斯特蘭
  • 曲普瑞林
  • 那法瑞林

6. 中樞性早熟症(Cpp) 治療市場依通路分類

  • 介紹
  • 醫院
  • 零售
  • 線上

7. 中樞早熟症(Cpp) 治療市場（按地區）

  • 介紹
  • 北美洲
    • 依藥物類型
    • 按分銷管道
    • 按國家
  • 南美洲
    • 按類型
    • 按最終用戶產業
    • 按國家
  • 歐洲
    • 依藥物類型
    • 按分銷管道
    • 按國家
  • 中東和非洲
    • 依藥物類型
    • 按分銷管道
    • 按國家
  • 亞太地區
    • 依藥物類型
    • 按分銷管道
    • 按國家

第8章 競爭格局及分析

  • 主要企業和策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭儀錶板

第9章 公司簡介

  • Pfizer Inc
  • AbbVie Inc
  • Sanofi
  • GlaxoSmithKline plc
  • Novartis AG
  • F Hoffmann-La Roche Ltd
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd
  • Ipsen Pharma
  • Arbor Pharmaceuticals.
  • Mylan NV
  • Arbor Pharmaceuticals
  • Tolmar Pharmaceuticals, Inc.
  • GP Pharm
  • DAEWOONG PHARMACEUTICAL CO LTD
  • Sun Pharmaceutical Industries Ltd.
簡介目錄
Product Code: KSI061617273

The Central Precocious Puberty (CPP) treatment market is expected to grow at a CAGR of 7.84%, reaching a market size of US$2,384.872 million in 2030 from US$1,634.872 million in 2025.

Central precocious puberty (CPP) treatment involves medicinal therapies aimed at managing and delaying the premature onset of puberty due to early activation of the hypothalamic-pituitary-gonadal (HPG) axis. Precocious sexual maturation is defined as the emergence of secondary sexual characteristics before the age of eight in girls and nine in boys. The primary approach to treatment utilizes gonadotropin-releasing hormone (GnRH) agonists, which inhibit the initiation of sex hormones and slow or halt the progression of puberty.Treatment for CPP can be either medicinal or surgical, depending on individual cases. Therapies are designed to postpone maturation, while surgery may be considered in specific situations. Diagnostic tools such as blood tests, MRIs, CT scans, and X-rays assist in determining the necessity for treatment. The therapies are available for both boys and girls and are primarily administered in hospitals, specialized clinics, home care settings, and other healthcare facilities.

Drivers of the Central Precocious Puberty (CPP) Treatment Market

  • Increasing Prevalence of Hormonal Disorders: The rising incidence of hormonal disorders is expected to significantly drive the growth of the CPP treatment market in the coming years. Hormonal disorders encompass a range of medical conditions resulting from hormonal imbalances within the body. Modern lifestyles, environmental exposures, and genetic or epigenetic factors contribute to the increasing prevalence of these disorders. The primary goal of CPP treatment is to manage early-onset puberty caused by hormonal imbalances by suppressing the signals that trigger puberty. Therefore, the growing incidence of hormonal abnormalities is a key factor propelling the CPP treatment market.

Geographical Outlook

  • Exponential Growth in Asia Pacific: The demand for CPP therapy in the Asia-Pacific region is growing impressively, with expectations for continued growth driven by increased awareness, improved healthcare systems, and a higher prevalence of the disorder. Enhanced diagnostic capabilities, greater awareness among parents and healthcare professionals, and potential environmental influences have contributed to this trend. Urbanization and lifestyle changes have altered diets and increased exposure to endocrine-disrupting substances that may lead to early puberty. Awareness campaigns and educational programs have also played a significant role in encouraging early diagnosis and treatment for CPP among children.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Central Precocious Puberty (CPP) treatment market is segmented and analyzed as follows:

By Drug Type

  • Leuprorelin
  • Histrein
  • Triptorelin
  • Nafarelin

By Distribution Channel

  • Hospitals
  • Retail
  • Online

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. CXO Perspective

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET BY DRUG TYPE

  • 5.1. Introduction
  • 5.2. Leuprorelin
  • 5.3. Histrein
  • 5.4. Triptorelin
  • 5.5. Nafarelin

6. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET BY DISTRIBUTION CHANNEL

  • 6.1. Introduction
  • 6.2. Hospitals
  • 6.3. Retail
  • 6.4. Online

7. CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Drug Type
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
      • 7.2.3.1. USA
      • 7.2.3.2. Canada
      • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Type
    • 7.3.2. By End-User Industry
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
      • 7.3.3.2. Argentina
      • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Drug Type
    • 7.4.2. By Distribution Channel
    • 7.4.3. By Country
      • 7.4.3.1. Germany
      • 7.4.3.2. France
      • 7.4.3.3. United Kingdom
      • 7.4.3.4. Italy
      • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Drug Type
    • 7.5.2. By Distribution Channel
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
      • 7.5.3.2. Israel
      • 7.5.3.3. UAE
      • 7.5.3.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Drug Type
    • 7.6.2. By Distribution Channel
    • 7.6.3. By Country
      • 7.6.3.1. China
      • 7.6.3.2. Japan
      • 7.6.3.3. South Korea
      • 7.6.3.4. India
      • 7.6.3.5. Indonesia
      • 7.6.3.6. Taiwan
      • 7.6.3.7. Thailand
      • 7.6.3.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Pfizer Inc
  • 9.2. AbbVie Inc
  • 9.3. Sanofi
  • 9.4. GlaxoSmithKline plc
  • 9.5. Novartis AG
  • 9.6. F Hoffmann-La Roche Ltd
  • 9.7. Mylan N.V.
  • 9.8. Teva Pharmaceutical Industries Ltd
  • 9.9. Ipsen Pharma
  • 9.10. Arbor Pharmaceuticals.
  • 9.11. Mylan N.V.
  • 9.12. Arbor Pharmaceuticals
  • 9.13. Tolmar Pharmaceuticals, Inc.
  • 9.14. GP Pharm
  • 9.15. DAEWOONG PHARMACEUTICAL CO LTD
  • 9.16. Sun Pharmaceutical Industries Ltd.